- Trials with a EudraCT protocol (13)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
13 result(s) found for: Cryoglobulinemia.
Displaying page 1 of 1.
EudraCT Number: 2008-000086-38 | Sponsor Protocol Number: FARM6KMZFY | Start Date*: 2008-04-10 | |||||||||||
Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | |||||||||||||
Full Title: A PHASE 2, SINGLE ARM, MULTI-CENTER STUDY ON THE BENEFIT/COST/SAFETY PROFILE OF LOW-DOSE RITUXIMAB FOR REFRACTORY MIXED CRYOGLOBULINEMIA | |||||||||||||
Medical condition: Mixed cryoglobulinemia (type II or III) associated with chronic HCV infection (positive serology and/or HCV viremia) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004519-29 | Sponsor Protocol Number: APHP180351 | Start Date*: 2021-03-18 | ||||||||||||||||
Sponsor Name:Assistance Publique - Hôpitaux de Paris / DRCI | ||||||||||||||||||
Full Title: Multicenter randomized double-blind study comparing the efficacy and safety of belimumab in the treatment of non-infectious active cryoglobulinemia vasculitis compared to placebo TRIBECA STUDY (Tr... | ||||||||||||||||||
Medical condition: Adult patients with non-infectious active cryoglobulinemia vasculitis. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004134-26 | Sponsor Protocol Number: sof-crio | Start Date*: 2015-02-19 | ||||||||||||||||
Sponsor Name:Centro Masve -Università degli Studi di Firenze-AOUC | ||||||||||||||||||
Full Title: A MULTICENTER, PROSPECTIVE, SINGLE ARM, OPEN-LABEL, PILOT STUDY ON THE BENEFIT/COST/SAFETY PROFILE OF SOFOSBUVIR FOR SYMPTOMATIC MIXED CRYOGLOBULINEMIA | ||||||||||||||||||
Medical condition: HCV chronic hepatitis and Mixed Cryoglobulinemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008045-38 | Sponsor Protocol Number: SS-BEL-01 | Start Date*: 2009-06-23 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA S. MARIA DELLA MISERICORDIA | |||||||||||||
Full Title: A Phase 2, proof of concept, 52-Week Open Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with primary Sjög... | |||||||||||||
Medical condition: Subjects with have a diagnosis of primary SS according to the updated American European Consensus Group Criteria (8). In addition, patients must be always positive for anti-SSA or anti-SSB antibod... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020659-30 | Sponsor Protocol Number: RITUXIMAB | Start Date*: 2009-10-26 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE | |||||||||||||
Full Title: COMBINED THERAPY WITH PEG-INTERFERON-α, RIBAVIRIN AND RITUXIMAB OF HEPATITIS C VIRUS-RELATED MIXED CRYOGLOBULINEMIA | |||||||||||||
Medical condition: patients anti-HCV, HCV RNA positivity, Na�ve, with cryoglobulinemic vasculitis (detection of serum cryoglobulins associated with purpura, arthralgias and weakness)and with chronic hepatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004998-53 | Sponsor Protocol Number: OMB116024 | Start Date*: 2013-02-05 |
Sponsor Name:National and Kapodistrian University of Athens | ||
Full Title: A phase II study of the efficacy of the combination of ofatumumab with fludarabine and cyclophosphamide in patients with relapsed or refractory Waldenström’s Macroglobulinemia. | ||
Medical condition: Relapsed or refractory Waldenström’s Macroglobulinemia. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-000609-28 | Sponsor Protocol Number: ESR-21-21284 | Start Date*: 2022-08-10 |
Sponsor Name:University Medical Centre Groningen | ||
Full Title: ANIfrolumab treatment for 24 weeks in patients with primary Sjögren’s syndrome – Efficacy and safety assessment in a randomized, double-blind, placebo-controlled phase-IIa proof-of-concept trial (A... | ||
Medical condition: Primary Sjögren's syndrome. Patients will be included if the fulfil the 2016 ACR/EULAR classification criteria for pSS and if they have active disease according to an ESSDAI score of 5 or more and/... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001033-27 | Sponsor Protocol Number: REMODEL-WM3 | Start Date*: 2016-08-25 |
Sponsor Name:FILO | ||
Full Title: REMODEL - WM3 An Open Label non-randomized Phase II Study exploring «chemo-free » treatment association with Idelalisib + Obinutuzumab in Patient with relapsed/refractory Waldenstrom’s Macroglobuli... | ||
Medical condition: Waldenstrom’s Macroglobulinemia (MW) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000506-37 | Sponsor Protocol Number: ECWM-1 | Start Date*: 2014-10-31 |
Sponsor Name:University Hospital Ulm | ||
Full Title: Efficacy of first line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for patients with Waldenström's Macroglobulinemia | ||
Medical condition: Waldenström's Macroglobulinemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Ongoing) IT (Ongoing) PT (Prematurely Ended) SE (Ongoing) GR (Restarted) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002232-85 | Sponsor Protocol Number: 5172-017 | Start Date*: 2013-01-15 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp. | |||||||||||||
Full Title: A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in ... | |||||||||||||
Medical condition: Hepatitis C Virus Infection (HCV) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) IT (Prematurely Ended) SE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) HU (Completed) ES (Completed) FI (Completed) NL (Completed) LT (Completed) EE (Completed) CZ (Completed) NO (Completed) AT (Completed) PL (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002324-36 | Sponsor Protocol Number: MK1026-003 | Start Date*: 2021-03-06 | |||||||||||||||||||||||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | |||||||||||||||||||||||||||||||||
Full Title: A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies | |||||||||||||||||||||||||||||||||
Medical condition: | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) IT (Ongoing) DK (Trial now transitioned) PL (Trial now transitioned) IE (Trial now transitioned) CZ (Trial now transitioned) HU (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004362-95 | Sponsor Protocol Number: ECWM-2 | Start Date*: 2019-04-12 | |||||||||||
Sponsor Name:University Hospital Ulm | |||||||||||||
Full Title: Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia | |||||||||||||
Medical condition: Waldenström's Macroglobulinemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) GR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003563-31 | Sponsor Protocol Number: 26866138CAN 2021 | Start Date*: 2007-03-09 | |||||||||||
Sponsor Name:European Myeloma Network | |||||||||||||
Full Title: Phase II Study of Combination Bortezomib (VELCADE, PS-341), Dexamethasone, and Rituximab (MabThera) (BDR) in Patients with previously untreated Waldenstrom’s Macroglobulinemia (WM). | |||||||||||||
Medical condition: Newly diagnosed Waldenstrom's macroglobulinemia (WM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) NL (Ongoing) ES (Ongoing) FR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.